NEW YORK (GenomeWeb News) – Alnylam today said that it has joined GlaxoSmithKline in contributing more than 1,500 issued or pending patents covering RNA interference technology to a patent pool for neglected tropical diseases.

The patent pool was established by London-based GlaxoSmithKline earlier this year to aid in the discovery and development of new medicines for treating 16 neglected tropical diseases, as defined by the US Food and Drug Administration, in the world's least developed countries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.

Sep
12
Sponsored by
PerkinElmer

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.